GH Research Provides Business Updates and Highlights Key Upcoming Milestones
DUBLIN, Ireland, Jan. 09, 2023 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.
Related news for (GHRS)
- Primary Endpoint Met in GH Research’s Phase 2b GH001Trial in TRD
- GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
- GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
- GH Research Reports Full Year 2022 Financial Results and Provides Business Updates